Chemotherapy and Targeted Therapy

The Biotech Heartland Shift: Why Innovation is Migrating Beyond the Boston-Cambridge Axis

• Chemotherapy and Targeted Therapy

The Biotech Heartland Shift: Why Innovation is Migrating Beyond the Boston-Cambridge Axis

Nila Kartika Wati July 7, 2026

For decades, the mention of "biotech" in the United States evoked one immediate mental image: the gleaming...

Read More Read more about The Biotech Heartland Shift: Why Innovation is Migrating Beyond the Boston-Cambridge Axis

Bridging the Gap: How Novel Immunotherapies Are Redefining the Treatment of TBI and Alzheimer’s Disease

• Chemotherapy and Targeted Therapy

Bridging the Gap: How Novel Immunotherapies Are Redefining the Treatment of TBI and Alzheimer’s Disease

Azzam Bilal Chamdy July 7, 2026

Traumatic brain injury (TBI) is a silent global epidemic. Affecting an estimated 69 million people annually, TBI...

Read More Read more about Bridging the Gap: How Novel Immunotherapies Are Redefining the Treatment of TBI and Alzheimer’s Disease

Novartis Enters the ADC Arena: A $1.5 Billion Strategic Pivot into Next-Generation Oncology

• Chemotherapy and Targeted Therapy

Novartis Enters the ADC Arena: A $1.5 Billion Strategic Pivot into Next-Generation Oncology

Iffa Jayyana July 6, 2026

In a decisive move to reshape its oncology pipeline, Swiss pharmaceutical titan Novartis has announced its intention...

Read More Read more about Novartis Enters the ADC Arena: A $1.5 Billion Strategic Pivot into Next-Generation Oncology

The Science of Precision: Why Patient Matching is the Bedrock of Credible Real-World Evidence

• Chemotherapy and Targeted Therapy

The Science of Precision: Why Patient Matching is the Bedrock of Credible Real-World Evidence

Laily UPN July 6, 2026

In the modern clinical landscape, the distance between a "hunch" and a "scientific finding" is measured by...

Read More Read more about The Science of Precision: Why Patient Matching is the Bedrock of Credible Real-World Evidence

The Double-Edged Sword: Eli Lilly’s Retatrutide and the New Frontier of Obesity Medicine

• Chemotherapy and Targeted Therapy

The Double-Edged Sword: Eli Lilly’s Retatrutide and the New Frontier of Obesity Medicine

Lina Irawan July 6, 2026

In the rapidly evolving landscape of metabolic health, Eli Lilly has reached a new milestone with its...

Read More Read more about The Double-Edged Sword: Eli Lilly’s Retatrutide and the New Frontier of Obesity Medicine

Global Race Against Time: CEPI Accelerates Development of Three Bundibugyo Ebola Vaccine Candidates

• Chemotherapy and Targeted Therapy

Global Race Against Time: CEPI Accelerates Development of Three Bundibugyo Ebola Vaccine Candidates

Layla Zulfa July 6, 2026

In a critical move to curb the escalating threat of the Bundibugyo ebolavirus (BDBV) in the Democratic...

Read More Read more about Global Race Against Time: CEPI Accelerates Development of Three Bundibugyo Ebola Vaccine Candidates

Beyond Weight Loss: How Retatrutide is Reshaping the Metabolic Landscape

• Chemotherapy and Targeted Therapy

Beyond Weight Loss: How Retatrutide is Reshaping the Metabolic Landscape

Muslim July 5, 2026

The pharmaceutical industry is witnessing a seismic shift in the treatment of metabolic diseases. At the American...

Read More Read more about Beyond Weight Loss: How Retatrutide is Reshaping the Metabolic Landscape

Shifting the Paradigm: How ADME-One is Moving Human PK Projection to the Front Lines of Drug Discovery

• Chemotherapy and Targeted Therapy

Shifting the Paradigm: How ADME-One is Moving Human PK Projection to the Front Lines of Drug Discovery

Asep Darmawan July 5, 2026

For decades, the pharmaceutical industry has operated under a rigid, linear philosophy: discover a potent molecule first,...

Read More Read more about Shifting the Paradigm: How ADME-One is Moving Human PK Projection to the Front Lines of Drug Discovery

Tensions and Breakthroughs: The 2026 American Diabetes Association Scientific Sessions

• Chemotherapy and Targeted Therapy

Tensions and Breakthroughs: The 2026 American Diabetes Association Scientific Sessions

Asro July 5, 2026

The 2026 American Diabetes Association (ADA) national conference was intended to be a watershed moment for the...

Read More Read more about Tensions and Breakthroughs: The 2026 American Diabetes Association Scientific Sessions

The Commissioner’s National Priority Voucher (CNPV): Regulatory Revolution or Strategic Chaos?

• Chemotherapy and Targeted Therapy

The Commissioner’s National Priority Voucher (CNPV): Regulatory Revolution or Strategic Chaos?

Siti Muinah July 4, 2026

Since its inception in June 2025, the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program has become...

Read More Read more about The Commissioner’s National Priority Voucher (CNPV): Regulatory Revolution or Strategic Chaos?